<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04503824</url>
  </required_header>
  <id_info>
    <org_study_id>14422019590827</org_study_id>
    <nct_id>NCT04503824</nct_id>
  </id_info>
  <brief_title>Assessing LncRNA DQ786243 and IL-17 Expression in Oral Lichen Planus: A Case Control Study</brief_title>
  <official_title>Assessing LncRNA DQ786243 and IL-17 Expression in Oral Lichen Planus: A Case Control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational case-control study. The current study aims to assess the salivary expression of&#xD;
      lncRNA DQ786243 and IL-17 in OLP, to better understand the pathogenesis of OLP and provide&#xD;
      effective targets for OLP therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oral lichen planus (OLP) is a common chronic inflammatory disease associated with&#xD;
      cell-mediated immunological dysfunction. OLP can be seen in different clinical presentations.&#xD;
      It can be classified as papular (reticular), atrophic (erythematous) and erosive (ulcerative,&#xD;
      bullous).1 Numerous predisposing factors have been blamed for causing OLP, including: stress,&#xD;
      diabetes, drugs, dental materials, autoimmune diseases, infectious agents and genetic&#xD;
      predisposition. 2 Regarding the pathogenesis of OLP, it is a T-cell mediated inflammatory&#xD;
      disease where antigen- specific and non-specific mechanisms are hypothesized to be involved3.&#xD;
      Antigen-specific mechanisms include antigen presentation by basal keratinocytes and&#xD;
      antigen-specific keratinocyte killing by CD8+ cytotoxic T-cells. Non-specific mechanisms&#xD;
      include mast cell degranulation, basement membrane disruption, chemokines and matrix&#xD;
      metalloproteinase (MMP) activation in OLP lesions.4 Various treatment regimens have been&#xD;
      proposed to improve the management of symptomatic OLP, but a permanent cure is not yet&#xD;
      available. Treatment regimens are non-specific and directed at eliminating inflammation and&#xD;
      immunosuppression.5 Corticosteroids constitute the main stay agent, other available treatment&#xD;
      modalities include immunosuppressants, cyclosporin, tacrolimus, and retinoids.6 Long&#xD;
      non-coding RNAs (lncRNAs) have been identified as new regulatory molecules. They modulate&#xD;
      protein coding gene at the chromatin remodeling level, or the transcriptional and post-&#xD;
      transcriptional control level. They play vital roles in cell differentiation, cell growth and&#xD;
      apoptosis. lncRNA DQ786243 is drawing attention in the pathogenesis of a variety of&#xD;
      inflammatory immune- mediated diseases such as Crohn's disease and OLP.7, 8 A recent study&#xD;
      suggested that lncRNA DQ786243 exert its function through interleukins (ILs) including IL-17.&#xD;
      T-helper 17 response and its hallmark IL-17 is gaining more evidence for its role and&#xD;
      association with many diseases such as&#xD;
&#xD;
      5 Crohn's disease, ulcerative colitis, systemic lupus erythematosus and OLP. IL-17 has been&#xD;
      found to participate in the development of autoimmune disease, inflammatory destruction and&#xD;
      tumor microenvironments.9, 10&#xD;
&#xD;
      Research question:&#xD;
&#xD;
      What is the salivary expression of lncRNA DQ786243 and IL-17 in Oral Lichen Planus?&#xD;
      Population (P): Oral lichen planus Control (C): Healthy individuals Outcome (O): Salivary&#xD;
      expression level of lncRNA DQ786243 and IL-17&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      The current study aims to assess the salivary expression of lncRNA DQ786243 and IL-17 in OLP,&#xD;
      to better understand the pathogenesis of OLP and provide effective targets for OLP therapy.&#xD;
&#xD;
      III. Methods:&#xD;
&#xD;
      7. Study design Observational case-control study. 8. Settings Participants will be recruited&#xD;
      from the diagnostic centre and Oral Medicine clinic of the Faculty of Dentistry- Cairo&#xD;
      University. The recruitment period is expected to extend from January 2020 to January 2021.&#xD;
&#xD;
      A) Participants 9. Eligibility criteria&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
        -  Patients diagnosed with OLP.&#xD;
&#xD;
        -  Patient who will agree to participate in the study.&#xD;
&#xD;
        -  Patients who will accept to sign the informed consent.&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        -  Patients suffering from any systemic disease.&#xD;
&#xD;
        -  Patients suffering from any local inflammatory disease or infection.&#xD;
&#xD;
        -  Pregnant and lactating women. ▪ Smokers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 5, 2020</start_date>
  <completion_date type="Anticipated">July 29, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 29, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Salivary expression of lncRNA DQ786243. Salivary expression of lncRNA DQ786243. Salivary expression of lncRNA DQ786243. Salivary expression of lncRNA DQ786243. ▪ Salivary expression of IL-17 and Salivary expression of lncRNA DQ786243.</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Patients With Oral Lichen Planus</condition>
  <arm_group>
    <arm_group_label>Group IIa: 13 papular OLP</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Group IIb: 13 atrophic OLP</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Group IIc: 13 erosive OLP</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Group I: 13 healthy individuals</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>saliva samples</intervention_name>
    <description>Salivary expression of lncRNA DQ786243 and IL-17 will be evaluated using qRT-PCR.</description>
    <arm_group_label>Group I: 13 healthy individuals</arm_group_label>
    <arm_group_label>Group IIa: 13 papular OLP</arm_group_label>
    <arm_group_label>Group IIb: 13 atrophic OLP</arm_group_label>
    <arm_group_label>Group IIc: 13 erosive OLP</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        thestudy composes of two groups: healthy controls and OLP. The expression of the two&#xD;
        markers will be compared between the two studied groups. In OLP group, the expression of&#xD;
        the two markers will be correlated with pain and clinical assessment scores. In addition,&#xD;
        OLP group will be subgrouped based on the clinical form: papular, atrophic, erosive. Data&#xD;
        of all participants will be entered on Excel sheet. Each participant will be provided an ID&#xD;
        number that will be used for data management and placed as a label for the samples.&#xD;
&#xD;
        Group I: 13 healthy individuals Group IIa: 13 papular OLP Group IIb: 13 atrophic OLP Group&#xD;
        IIc: 13 erosive OLP&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with OLP.&#xD;
&#xD;
               -  Patient who will agree to participate in the study.&#xD;
&#xD;
               -  Patients who will accept to sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients suffering from any systemic disease.&#xD;
&#xD;
               -  Patients suffering from any local inflammatory disease or infection.&#xD;
&#xD;
               -  Pregnant and lactating women. ▪ Smokers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>engy abdeldayem</last_name>
    <phone>01222376959</phone>
    <email>engyabdeldayem@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cairo University</name>
      <address>
        <city>Cairo</city>
        <zip>12223</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>engy abdeldayem</last_name>
      <phone>01222376959</phone>
      <email>engyabdeldayem@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 5, 2020</study_first_submitted>
  <study_first_submitted_qc>August 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2020</study_first_posted>
  <last_update_submitted>August 5, 2020</last_update_submitted>
  <last_update_submitted_qc>August 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Engy Mahmoud Abdel Wahed Abdel dayem</investigator_full_name>
    <investigator_title>assistant lecterur</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lichen Planus, Oral</mesh_term>
    <mesh_term>Lichen Planus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

